Vir Biotechnology Inc Forecast, price target & analysts
Vir Biotechnology Inc Target price 2026 - Analyst rating & recommendation
Vir Biotechnology Inc Classifications & Recommendation
Vir Biotechnology Inc Price Target
| Target Price | $20.40 |
| Price | $10.52 |
| Potential |
93.92%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Vir Biotechnology Inc 2027 .
The average Vir Biotechnology Inc target price is $20.40.
This is
93.92%
register free of charge
$31.50
199.43%
register free of charge
$15.15
44.01%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Vir Biotechnology Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Vir Biotechnology Inc stock has an average upside potential 2027 of
93.92%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 68.56 | 242.48 |
| 7.61% | 253.68% | |
| EBITDA Margin | -698.82% | -143.02% |
| 6.03% | 79.53% | |
| Net Margin | -638.84% | -115.93% |
| 9.17% | 81.85% |
11 Analysts have issued a sales forecast Vir Biotechnology Inc 2026 . The average Vir Biotechnology Inc sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Vir Biotechnology Inc EBITDA forecast 2026. The average Vir Biotechnology Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Vir Biotechnology Inc Analysts have issued a net profit forecast 2026. The average Vir Biotechnology Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.16 | -1.66 |
| 17.49% | 47.47% | |
| P/E | negative | |
| EV/Sales | 5.17 |
11 Analysts have issued a Vir Biotechnology Inc forecast for earnings per share. The average Vir Biotechnology Inc EPS is
This results in the following potential growth metrics and future valuations:
Vir Biotechnology Inc...
Current Vir Biotechnology Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jun 11 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Jun 03 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 04 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Feb 25 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Feb 24 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Feb 24 2026 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Feb 24 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jun 11 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Jun 03 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 04 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Feb 25 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Feb 24 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Feb 24 2026 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Feb 24 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
